CEL-SCI Corporation (Vienna, VA; 703-506-9460) announced the issuance of three new United States patents, further expanding the patent protection related to its HIV-1 based therapeutic and preventive vaccines. These new patents expand the company's intellectual property protection to the C strain (clade) of the HIV virus, which is the most prevalent strain in the world and is also the dominant strain in the developing world.
The first patent describes an improved version of the company's already patented HGP-30 peptide that contains within its sequence several epitopes (small pieces of around 8-10 amino acids found within foreign proteins) against which the immune …
No comments:
Post a Comment